In one paragraphArticle in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Jamie N Guillen MagañaRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0002-6650-0871 Markella ZannikouRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0003-1452-2056 Aneta BaranRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0001-7308-6894 Sara SmallRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0003-1246-0250 Michael SchieberRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0001-9994-8579 Matthew J SchipmaRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0002-0865-1057 Elizabeth T BartomRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0002-5618-2582 Masha KocherginskyRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0002-3510-9562 Diana SaleiroRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0002-6756-3620 Elspeth M BeauchampRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0009-0007-3180-2742 Frank EckerdtRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0001-6853-850X Leonidas C PlataniasRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0002-9740-7573 Funding
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9MCARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4MSignal Transduction of Type I Interferons in Malignant CellsR01CA077816 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 1998 to 2024
$6.6MTargeting Novel Protein Complexes for the Treatment of Acute Myeloid LeukemiaR01CA121192 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2006 to 2023
$4.1MBioinformatics Analysis of Next Generation Sequencing Data from Cancer CellsR50CA221848 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Elizabeth Thomas Bartom · 2017 to 2026
$1.8MCSRD VA I01 CX000916National Cancer Institute (NCI) CA077816National Cancer Institute (NCI) CA121192NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA077816NCI NIH HHS R01 CA121192NCI NIH HHS R50 CA221848NCI NIH HHS T32 CA009560U.S. Department of Veterans Affairs (VA) I01-CX000916
6 · The paper itselfAbstract
We examined the role of SLFN12, a member of the Schlafen (SLFN) family of interferon-regulated genes and proteins in leukemogenesis, and its potential as a therapeutic target in acute myeloid leukemia (AML). We explored the effects of velcrins, a class of small molecules able to modulate SLFN12 biological activity, on AML cells. Velcrin treatment of AML cells stabilized SLFN12 and promoted SLFN12 complex formation with phosphodiesterase 3A or phosphodiesterase 3B. Such effects were associated with growth-inhibitory and proapoptotic responses, as well as potent suppressive effects on leukemic cell growth. In addition, velcrin treatment suppressed clonogenic capacity of primitive leukemic progenitors and significantly extended survival in a mouse AML xenograft model. Taken together, these findings establish an important role of SLFN12 in leukemogenesis and raise the potential for the use of velcrins as a therapeutic strategy for AML. SIGNIFICANCE: Our studies identify SLFN12 as a potential target in AML with important clinical-translational implications.
Indexed as
Leukemia, Myeloid, AcuteAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceXenograft Model Antitumor Assays
Identifiers
PMID41150877
PMCPMC12620962
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390